From €3.5 to €30.4 Million: Germany’s Rise in Two Years
The numbers are remarkable. In February 2024, Canada exported cannabis flowers worth approximately 3.5 million Canadian dollars to Germany. Two years later, in February 2026, this value had reached 30.4 million Canadian dollars—out of a total export volume of around 51.6 million. This represents a 763 percent increase within 24 months.
📑 Inhaltsverzeichnis
This development is no accident. Since the Cannabis Consumption Act came into force in April 2024, Germany has structurally become Europe’s most important legal cannabis market. The CanG interim report from April 2026 demonstrates that legalization has delivered results despite political criticism. On the demand side, the legislation has created clear structures that international producers require for export planning. Canada—with its mature, EU-GMP-certified production infrastructure—has leveraged this opportunity strategically.
The 200-ton milestone that Germany surpassed in the first quarter of 2026 was an early indicator of this trend. The Canadian export data now available gives this figure new significance: Germany is not merely a growing market, but a global anchor for an entire production industry.
Portugal’s Collapse and the End of a Supply Chain Model
Just a year ago, Portugal was one of Europe’s most critical cannabis trading hubs. Canadian producers initially shipped their flowers to Portugal, where they were further processed to EU-GMP standards and then redistributed to other European countries—particularly Germany. This model offered logistical advantages and enabled producers to participate in the European market without full EU-GMP certification of their own.
But Portugal’s share of Canadian flower exports has plummeted dramatically. What’s driving this shift?
The primary reason is straightforward: increasingly, Canadian producers now possess the necessary EU-GMP certifications for direct export to Germany. The detour through Portugal has become unnecessary. What was once a regulatory efficiency gain has become an expensive middleman step. Simultaneously, direct discount negotiations with German health insurance providers are simpler when supplying directly. Australia does appear as a growing export destination—but at significantly lower prices, suggesting different market structures and more intense competition.
What This Shift Means for the German Market
For Germany, this development is significant in multiple ways. On one hand, it demonstrates that the market has achieved the depth and planning certainty needed to convince international investors and producers. A 2026 market report had already projected German medicinal cannabis revenues of nearly one billion euros—the import data shows these projections rest on solid foundations.
On the other hand, the question of dependency arises. Germany today imports more cannabis from Canadian sources than any other country—yet it is building only limited domestic capacity. Cultivation associations under Pillar 1 of the CanG produce exclusively for their members and play no role in the medical supply system. Large-scale, EU-GMP-certified cultivation in Germany remains absent from the horizon.
This creates structural dependency: if Canadian export prices rise, geopolitical conditions change, or the Canadian dollar fluctuates, the German market feels it first. Those observing the rapid import expansion since 2024 recognize how quickly this dependency has become embedded in the system. The 62-percent benchmark is a success for Germany’s market—and simultaneously a pointer to its Achilles heel.
Frequently Asked Questions
How much medicinal cannabis does Canada export to Germany?
In February 2026, Canada exported cannabis flowers worth approximately 30.4 million Canadian dollars to Germany. This represents 62.3 percent of all Canadian flower exports in that month.
Why has Germany’s share of Canada’s cannabis exports grown so dramatically?
Since the Cannabis Consumption Act took effect in 2024, demand for legal cannabis in Germany has surged significantly. Simultaneously, more and more Canadian producers now hold EU-GMP certifications enabling direct export—without the previous detours through processing countries like Portugal.
Why has Portugal’s share of Canadian cannabis exports declined?
Portugal was formerly a critical transit country, reprocessing Canadian cannabis to EU-GMP standards and forwarding it to Germany. As more Canadian producers can now export directly, the need for this intermediary step has diminished sharply.
Is Germany the world’s largest importer of medicinal cannabis?
Germany is recognized as Europe’s largest legal-commercial cannabis market and is by far the most important customer for Canadian flower exports. Germany accounts for more than 62 percent of Canadian flower shipments—a share unmatched by any other market globally in this form.
Could Germany meet its import needs domestically in the future?
To date, there is no large-scale, EU-GMP-certified domestic production in Germany. Cultivation associations produce exclusively for their members and play no role in the medical supply system. In the medium term, Canada is expected to remain an important supplier.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
